Hodgkin lymphoma highlights at ASH 2022 and future outlooks

0 Views

07/15/23

In this video, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Centre, Toronto, Canada, shares some highlights in Hodgkin lymphoma (HL) presented at the ASH 2022 Annual Meeting. Dr Kuruvilla comments on the overall survival (OS) data recently reported in the ECHELON-1 trial (NCT01712490) and the updated results of the RATHL trial (CRUK/07/033), and concludes by discussing future considerations for the treatment of HL. This interview took place at the 64th ASH Annual Meeting and Exposition congress held in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.